Psych MEQs / SAQs · Foundations — research methods and study design
Choosing and defending study designs in psychiatry (MEQ)
FRANZCP/MRCPsych-style MEQ on design–question matching, bias threats, and CONSORT/STROBE/COREQ reporting for psychiatry research scenarios.
On this page & tools
Target exams
Model answer
Reveal model answer
(A) CBT adjunct for relapse prevention. (i) Parallel-group RCT (ideally assessor-blind; full double-blind of therapy content often impossible) randomising remitted adults to CBT plus medication management versus medication management alone, with pre-specified 6-month relapse as primary outcome.[1][3] (ii) Main threats if weak: performance/detection bias (unblinded supportive contact and unblinded relapse ratings) and attrition with completer-only analysis.[3] (iii) CONSORT for trial reporting (flow, randomisation, outcomes).[3]
(B) Clozapine severe neutropenia incidence and predictors. (i) Prospective cohort of new clozapine starters with active haematological surveillance — exposure defined at inception, outcomes counted forward to estimate incidence and associations with baseline predictors.[2] A case-control design could study rare agranulocytosis associations but does not directly yield incidence without a defined source population and sampling fraction.[1] (ii) Main threats: loss to follow-up, incomplete blood monitoring data, and confounding of predictors (comorbidity, co-prescribing).[6][2] (iii) STROBE (cohort checklist).[4]
(C) Carer lived experience. (i) Qualitative design (e.g. semi-structured interviews with purposive sampling; thematic analysis or culturally adapted methodology with Indigenous governance).[5] (ii) Main threats: poor reflexivity, tokenistic sampling, analysis without credibility checks, extracting themes as if they were prevalence rates.[5] (iii) COREQ for interview/focus-group reporting.[5]
(iv) Why RCT is not default for B and C. Question B asks for incidence and predictors under real-world clozapine use, not experimental assignment of a harmful outcome; randomising people to clozapine solely to count neutropenia would be unethical and unnecessary when the exposure is already indicated clinically — a cohort matches the question.[2][1] Question C asks for meaning and experience, which quantitative trials do not answer; forcing an RCT would be a design–question mismatch.[5][1] Hierarchy rank does not override question fit or ethics.
Common errors
Defaulting every question to RCT; calling a monitoring programme a case-control study; using CONSORT for qualitative work; equating COREQ with quality of insight; claiming cohorts cannot estimate incidence; ignoring Indigenous research governance for question C.[1][3][4][5]
References
- [1]Grimes DA, Schulz KF An overview of clinical research: the lay of the land Lancet, 2002.PMID 11809203
- [2]Grimes DA, Schulz KF Cohort studies: marching towards outcomes Lancet, 2002.PMID 11830217
- [3]Schulz KF, Altman DG, Moher D; CONSORT Group CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials BMJ, 2010.PMID 20332509
- [4]von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP; STROBE Initiative The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies Lancet, 2007.PMID 18064739
- [5]Tong A, Sainsbury P, Craig J Consolidated criteria for reporting qualitative research (COREQ): a 32-item checklist for interviews and focus groups Int J Qual Health Care, 2007.PMID 17872937
- [6]Grimes DA, Schulz KF Bias and causal associations in observational research Lancet, 2002.PMID 11812579